<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Zhu, Andrew X.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">RAM Fails to Improve OS as Second-Line Treatment for Hepatocellular Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-20</style></pages><abstract><style  face="normal" font="default" size="100%">As second-line therapy for hepatocellular carcinoma, ramucirumab did not improve overall survival compared with placebo in a phase 3 randomized study, but benefit was observed in a selected population with an elevated baseline level of alpha-fetoprotein. The results of the randomized, phase 3 Ramucirumab Second-Line Treatment in Patients With Hepatocellular Carcinoma After First-Line Therapy With Sorafenib study [REACH; NCT01140347] are discussed in this article.</style></abstract><number><style face="normal" font="default" size="100%">36</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>